Education
About Us
Working with TipRanks
Follow Us
Mink Therapeutics, Inc. (INKT)
:INKT
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.71Last Year’s EPS
-1.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -1.29%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant strategic and clinical advancements, including leadership strengthening and promising clinical progress in solid tumors and respiratory distress treatment. Financial improvements were noted, although concerns remain regarding cash position and funding uncertainty for the GvHD study.Company Guidance
During MiNK Therapeutics' fourth quarter 2024 financial results call, significant progress and strategic advancements were highlighted. The company expanded its leadership team and partnerships, notably welcoming Dr. Robert Kadlec to the Board and collaborating with Autonomous Therapeutics to enhance their iNKT cell therapy with encrypted RNA technology. Their clinical programs showed promising results, including their iNKT cell therapy, 797, demonstrating enhanced immune activation and synergy with checkpoint inhibitors in challenging cancer treatments. The company reported a cash balance of $4.6 million with a net loss of $10.8 million for the year. MiNK plans to advance its clinical pipeline in 2025, focusing on gastric cancer and Graft versus Host Disease, alongside strategic innovations like their FAP-CAR-iNKT and PRAME-TCR programs. Operational efficiency and fiscal responsibility remain central to their strategy, with cash runway projected through the end of 2025.Strategic Leadership Addition
Dr. Robert Kadlec, a renowned leader in biodefense and pandemic preparedness, joined the Board of Directors, adding strategic depth to explore applications of iNKT platform in biodefense and infectious diseases.
Partnership with Autonomous Therapeutics
Entered collaboration to combine encrypted RNA technology with iNKT cell therapy, aiming to create next-generation treatments for metastatic cancer.
Clinical Progress in Solid Tumors
Presented data showing that iNKT cells enhance immune activation and can overcome resistance in challenging cancers like gastric cancer.
Advancement in Respiratory Distress Treatment
Phase 1 study showed 80% survival rate for patients on severe life support, compared to 10% of in-hospital controls, demonstrating potential in addressing high-impact health challenges.
Financial Management and Progress
Reduced cash used in operations from $15.8 million in 2023 to $9.6 million in 2024, and net loss decreased from $22.5 million to $10.8 million.
---
INKT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INKT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $8.52 | $8.24 | -3.29% |
| Nov 14, 2024 | $7.94 | $7.50 | -5.54% |
| Aug 13, 2024 | $8.35 | $8.49 | +1.68% |
| May 14, 2024 | $9.80 | $11.20 | +14.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mink Therapeutics, Inc. (INKT) report earnings?
Mink Therapeutics, Inc. (INKT) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Mink Therapeutics, Inc. (INKT) earnings time?
Mink Therapeutics, Inc. (INKT) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INKT EPS forecast?
INKT EPS forecast for the fiscal quarter 2025 (Q1) is -0.71.
---